Zila, Inc. (NASDAQ GM: ZILA) reported its financial results for the
fiscal year and fourth quarter ended July 31, 2006. Fiscal 2006
Financial Results: -- Zila, Inc.'s (the "Company") net revenue for
fiscal 2006 was $28.2 million, compared with $43.5 million for
fiscal 2005. For the year, net revenue for Zila Pharmaceuticals,
Inc. ("Zila Pharmaceuticals") increased by 34%, while the net
revenue of Zila Nutraceuticals, Inc. ("Zila Nutraceuticals")
decreased by 44%. -- Zila Pharmaceuticals' revenue increased 34%,
to $6.7 million, compared with $5.0 million in the prior year.
Pharmaceuticals represented 24% of revenue in fiscal 2006 compared
with 12% of revenue for fiscal 2005. The growth in net revenue in
Zila Pharmaceuticals was driven by increases in all product lines.
Sales of ViziLite(R) and ViziLite(R) Plus were $2.7 million, a 128%
increase over sales of ViziLite(R) in fiscal 2005. Peridex(R) sales
increased by 5% to $4.0 million in fiscal 2006 compared with fiscal
2005. Gross margins for Zila Pharmaceuticals for the fiscal year
ended July 31, 2006 were 53%, compared with 64% for the fiscal year
ended July 31, 2005. This decrease was primarily caused by
incentives to support the launch of ViziLite(R) Plus. -- The
Nutraceuticals business was divested on October 2, 2006 to NBTY,
Inc. in a cash transaction valued at up to $40.5 million. Zila
Nutraceuticals' fiscal 2006 revenue was $21.5 million compared with
$38.5 million for the fiscal year ended July 31, 2005. The Company
believes the decline in revenue was primarily due to decreased
sales to several of its largest customers as a result of the
divestiture process. Gross margins for Zila Nutraceuticals were 61%
compared with 68% for the fiscal year ended July 31, 2005. This
decrease was caused largely by promotional discounts offered in an
effort to stimulate sales. -- Total operating expenses for Zila
Biotechnology, Inc. ("Zila Biotechnology") for fiscal 2006 were
$9.5 million, a 9% increase, compared with $8.7 million for fiscal
2005. This increase reflects the commencement of the new Phase III
clinical trial for OraTest(R). Research and development expenses
related to the OraTest(R) program were $7.2 million in fiscal 2006
compared to $6.7 million in fiscal 2005. -- Zila completed the
fiscal year with a net loss from continuing operations of $27.7
million, or $0.61 per diluted common share, compared with a net
loss of $7.3 million, or $0.16 per diluted common share in fiscal
2005. Discontinued operations produced a net loss of $1.6 million,
or $0.03 per diluted common share, in fiscal 2006 but generated
income of $8.4 million, or $0.18 per diluted common share, in
fiscal 2005, largely from the gain on the divestiture of the
Zilactin(R) business in June 2005. -- Cash, cash equivalents and
restricted cash at July 31, 2006 totaled $7.5 million, compared to
cash, cash equivalents, restricted cash and short-term investments
of $13.4 million at July 31, 2005. Fiscal 2006 Business Highlights:
-- In December 2005, the Company reached an agreement with the
United States Food and Drug Administration's ("FDA") regarding the
FDA's Special Protocol Assessment process, on the Company's new
Phase III clinical trial for OraTest(R), an oral cancer detection
drug. To date, enrollment to accrue the fewer than 4,000 patients
needed for the multi-center trial is proceeding on schedule. The
trial may be approaching a point where an interim analysis of the
test results could be required. -- In January 2006, the Company
rolled out ViziLite(R) Plus. This product combines its oral
screening technology, ViziLite(R) with TBlue630, a marking system
using Zila Tolonium Chloride (ZTC(R)), the only patented,
pharmaceutical-grade form of toluidine blue. TBlue630 was
FDA-cleared and contains the same active ingredient and formulation
that is used in the Company's OraTest(R) product. -- During fiscal
2006, the Company expanded ViziLite(R) Plus insurance coverage and
added 500 group practices to its customer base, including some of
the largest practices in the country. -- In line with the Company's
strategy to focus on cancer detection and divest non-core assets,
the Company divested IST in July 2006 and closed on the sale of
Zila Nutraceuticals in October 2006. Further, the Company entered
into a non-binding letter of intent to acquire a privately-held
dental products company in order to reach the nation's dentists
through a national sales force. There can be no assurance that this
potential acquisition will be completed. "Fiscal 2006 began a
revolutionary transition for Zila as we continued our strategy to
focus our business on high-growth cancer detection technologies. We
succeeded in that mission with growth in ViziLite� Plus product
awareness, dental office integration and insurance reimbursement,
while OraTest� moved closer to completion of its regulatory
objectives. We were also able to divest our Nutraceuticals business
at a fair valuation in October 2006,� said Zila Chairman, President
and CEO, Doug Burkett, Ph.D. Dr. Burkett continued, �As our ongoing
efforts will be focused on growing ViziLite� Plus and subsequently
OraTest�, we sought to acquire a dental company with a national
sales force in order to provide the infrastructure required to
establish our oral cancer detection products as the standard of
care within dental offices nationally. We reviewed over 200
potential dental companies and we have entered into a non-binding
letter of intent to acquire a privately-held dental products
business. We believe this potential acquisition will enable us to
reach the nation�s dentists through a highly regarded and
profitable company with a national sales force.� The acquisition,
if completed, would provide Zila with a national sales and
marketing organization that has a small suite of proprietary, high
margin dental products that would complement Zila�s cancer
screening and detection products. The sales and marketing programs
currently conducted by the target company reflect the focused,
hands-on approach that is required to integrate ViziLite� Plus into
dental practices and to establish the test as the standard of care.
The target company generates approximately $35 million in annual
revenue and is profitable. The anticipated acquisition price is $34
million. There can be no assurance that this potential acquisition
will be completed. Fiscal 2006 Fourth Quarter Results: -- The
Company's net revenue for the fourth quarter of fiscal 2006 was
$4.2 million, compared with net revenue of $11.2 million in the
fourth quarter of fiscal 2005. -- Zila Pharmaceuticals' revenue
decreased 40% in the fourth quarter to $1.0 million, compared with
$1.7 million during the same quarter of fiscal 2005. The decline in
fourth quarter revenue was primarily due to lower ViziLite(R) Plus
sales as we prepared for a potential acquisition of a company with
a national sales force that would provide Zila the option to offer
ViziLite(R) Plus directly to dentists. Zila focused its fourth
quarter efforts toward the adoption and integration of ViziLite(R)
Plus within dental offices resulting in continued increases in
acceptance, growth and repeat orders by dental offices as they
purchased from dental distributors. However, deliberate reductions
in sales into our existing distribution channel were made as we
optimized our flexibility to modify and expand our means of
distribution. The upward trend of quarterly ViziLite(R), and
subsequently ViziLite(R) Plus, revenues that were generated during
the preceding seven quarters has been temporarily disrupted to
maximize our future growth options. -- Zila Nutraceuticals' revenue
in the fourth quarter was $3.2 million, compared with $9.5 million
during the prior year's fourth quarter. Zila believes the decrease
in sales was affected by the process of seeking to divest the
business unit. Gross margins for Zila Nutraceuticals were 53% for
the three months ended July 31, 2006 compared with 63% for the
three months ended July 31, 2005. This decrease was caused
primarily by discounts offered to customers to stimulate sales. --
Total operating expenses for Zila Biotechnology in the fourth
quarter was $2.1 million compared with $2.3 million in 2005. This
decrease is primarily due to reduced cost within the Zila Tolonium
Chloride manufacturing facility that was undergoing a
recommissioning in the prior year quarter. The Company made
progress in the furtherance of its OraTest� regulatory program
during the quarter. We believe that the current study enrollment
can be completed in approximately one year from the beginning of
enrollment at most clinical sites in spring 2006, although no
assurances can be given in this regard. The on-going trial is
expected to require fewer than 4,000 patients. Upon completion of
the clinical program and assuming that all clinical requirements
are achieved, we estimate that it will require approximately six
months to complete our regulatory objectives in order to prepare
the NDA supplement for submission to the FDA. Conference Call Zila,
Inc. will host a conference call to discuss these results today at
4:30 p.m. EDT (1:30 p.m. PDT). To participate in the
teleconference, please call toll-free 877-407-8031 (or 201-689-8031
for international callers) approximately 10 minutes prior to the
above start time. You may also listen to the teleconference live
via the internet at www.zila.com. Investors should visit the
website prior to the call to download any necessary audio software.
A telephone playback of the call will be available for 48 hours,
two hours after the completion of the call, and can be accessed by
calling 877-660-6853 (or 201-612-7415 for international callers)
and providing passcode 286 and conference ID 215747. The webcast
will be archived on the Company�s website for one week. About Zila,
Inc. Zila, Inc., headquartered in Phoenix, is a leading cancer
diagnostic company initially focused on oral cancer: Zila
Pharmaceuticals is dedicated to establishing ViziLite�Plus as the
new standard of care within dental offices nationally for the early
detection of oral abnormalities that could lead to cancer. Zila
Biotechnology is focused on achieving regulatory approval for the
next generation oral cancer diagnostic, OraTest�, followed by the
development of additional applications of its cancer detection
technologies including products for the early detection of cervical
and esophageal cancer. For more information about Zila, visit
www.zila.com. This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenue, profitability, cash
flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. The Company makes no
commitment, and disclaims any duty, to update or revise any
forward-looking statements to reflect future events or changes in
expectations. For a more detailed description of these and other
cautionary factors that may affect Zila's future results, please
refer to Zila's Form 10-K for its fiscal year ended July 31, 2006
ZILA, INC. AND SUBSIDIARIESIncome Statement (Unaudited)(in
thousands, except for per share data) � Three Months endedJuly 31,
Fiscal Year endedJuly 31, � 2006� � 2005� � 2006� � 2005� � Net
revenues $ 4,207� $ 11,194� $ 28,188� $ 43,489� Cost of product
sold � 2,181� � 4,021� � 11,500� � 14,273� Gross profit 2,026�
7,173� 16,688� 29,216� � Operating Costs and Expenses: Marketing
and selling 2,334� 2,128� 17,986� 15,718� General and
administrative 3,890� 2,966� 13,494� 11,040� Research and
development 1,565� 1,985� 7,776� 7,181� Depreciation and
amortization � 742� � 599� � 2,727� � 2,414� � 8,531� � 7,678� �
41,983� � 36,353� � Loss from operations � (6,505) � (505) �
(25,295) � (7,137) � Other income (expense): Interest income 113�
59� 344� 187� Interest expense (1,255) (52) (2,152) (195)
Derivative expense (137) -� (137) -� Gain (loss) on sale of assets
(1) (2) (27) (6) Other expense � (198) � (40) � (477) � (114) �
(1,478) � (35) � (2,449) � (128) � Income (loss) from continuing
operations before tax (7,983) (540) (27,744) (7,265) � Income tax
expense � -� � (7) � (4) � (8) � Income (loss) from continuing
operations (7,983) (547) (27,748) (7,273) � Discontinued
operations: Income (loss) from operations (411) (538) (969) (1,331)
Net gain on disposal of discontinued operations (629) 9,781� (629)
9,781� Income tax expense � -� � (78) � -� � (78) Income (loss)
from discontinued operations � (1,040) � 9,165� � (1,598) � 8,372�
� Net income (loss) (9,023) 8,618� (29,346) 1,099� Preferred stock
dividends � (10) � (10) � (39) � (39) � Net income (loss)
attributable to common shareholders $ (9,033) $ 8,608� $ (29,385) $
1,060� � Basic and diluted net income (loss) per common share: From
continuing operations $ (0.17) $ (0.01) $ (0.61) $ (0.16) From
discontinued operations � (0.02) � 0.20� � (0.03) � 0.18� Net
income (loss) $ (0.19) $ 0.19� $ (0.64) $ 0.02� � Weighted average
shares outstanding - basic and diluted 45,749� 45,606� 45,703�
45,565� EBITDA (a) $ (7,061) $ 9,217� $ (24,498) $ 3,939� � (a)
EBITDA is defined as earnings (loss) before net interest, taxes
(income), depreciation and amortization. EBITDA Reconciliation(in
thousands) � Three Months endedJuly 31, Fiscal Year endedJuly 31, �
2006� � 2005� � 2006� � 2005� � EBITDA $ (7,061) $ 9,217� $
(24,498) $ 3,939� Interest income 113� 59� 344� 188� Interest
expense (1,256) (52) (2,152) (196) Depreciation and amortization
(819) (599) (3,036) (2,746) Income tax expense � -� � (7) � (4) �
(86) � Net Income (Loss) $ (9,023) $ 8,618� $ (29,346) $ 1,099� Net
Revenues by Business UnitUnaudited(in thousands) � Three Months
endedJuly 31, � � Fiscal Year endedJuly 31, � � % % � 2006� 2005�
Change � 2006� � 2005� Change � Nutraceuticals $ 3,207� $ 9,517�
(66) $ 21,472� $ 38,471� (44) � Pharmaceuticals 1,001� 1,677� (40)
6,716� 5,018� 34� � Total Company 4,208� 11,194� (62) 28,188�
43,489� (35) Balance Sheet DataUnaudited(in thousands) � � July 31,
July 31, � 2006� � 2005� Current assets $ 22,970� $ 32,639�
Property - net 8,411� 9,692� Intangibles - net 22,037� 22,614�
Other � 2,946� � 473� � Total assets $ 56,364� $ 65,418� � �
Current liabilities $ 29,824� $ 9,815� Long-term liabilities 3,289�
3,881� Shareholders equity � 23,251� � 51,722� � Total liabilities
and equity $ 56,364� $ 65,418� Zila, Inc. (NASDAQ GM: ZILA)
reported its financial results for the fiscal year and fourth
quarter ended July 31, 2006. -0- *T Fiscal 2006 Financial Results:
-- Zila, Inc.'s (the "Company") net revenue for fiscal 2006 was
$28.2 million, compared with $43.5 million for fiscal 2005. For the
year, net revenue for Zila Pharmaceuticals, Inc. ("Zila
Pharmaceuticals") increased by 34%, while the net revenue of Zila
Nutraceuticals, Inc. ("Zila Nutraceuticals") decreased by 44%. --
Zila Pharmaceuticals' revenue increased 34%, to $6.7 million,
compared with $5.0 million in the prior year. Pharmaceuticals
represented 24% of revenue in fiscal 2006 compared with 12% of
revenue for fiscal 2005. The growth in net revenue in Zila
Pharmaceuticals was driven by increases in all product lines. Sales
of ViziLite(R) and ViziLite(R) Plus were $2.7 million, a 128%
increase over sales of ViziLite(R) in fiscal 2005. Peridex(R) sales
increased by 5% to $4.0 million in fiscal 2006 compared with fiscal
2005. Gross margins for Zila Pharmaceuticals for the fiscal year
ended July 31, 2006 were 53%, compared with 64% for the fiscal year
ended July 31, 2005. This decrease was primarily caused by
incentives to support the launch of ViziLite(R) Plus. -- The
Nutraceuticals business was divested on October 2, 2006 to NBTY,
Inc. in a cash transaction valued at up to $40.5 million. Zila
Nutraceuticals' fiscal 2006 revenue was $21.5 million compared with
$38.5 million for the fiscal year ended July 31, 2005. The Company
believes the decline in revenue was primarily due to decreased
sales to several of its largest customers as a result of the
divestiture process. Gross margins for Zila Nutraceuticals were 61%
compared with 68% for the fiscal year ended July 31, 2005. This
decrease was caused largely by promotional discounts offered in an
effort to stimulate sales. -- Total operating expenses for Zila
Biotechnology, Inc. ("Zila Biotechnology") for fiscal 2006 were
$9.5 million, a 9% increase, compared with $8.7 million for fiscal
2005. This increase reflects the commencement of the new Phase III
clinical trial for OraTest(R). Research and development expenses
related to the OraTest(R) program were $7.2 million in fiscal 2006
compared to $6.7 million in fiscal 2005. -- Zila completed the
fiscal year with a net loss from continuing operations of $27.7
million, or $0.61 per diluted common share, compared with a net
loss of $7.3 million, or $0.16 per diluted common share in fiscal
2005. Discontinued operations produced a net loss of $1.6 million,
or $0.03 per diluted common share, in fiscal 2006 but generated
income of $8.4 million, or $0.18 per diluted common share, in
fiscal 2005, largely from the gain on the divestiture of the
Zilactin(R) business in June 2005. -- Cash, cash equivalents and
restricted cash at July 31, 2006 totaled $7.5 million, compared to
cash, cash equivalents, restricted cash and short-term investments
of $13.4 million at July 31, 2005. Fiscal 2006 Business Highlights:
-- In December 2005, the Company reached an agreement with the
United States Food and Drug Administration's ("FDA") regarding the
FDA's Special Protocol Assessment process, on the Company's new
Phase III clinical trial for OraTest(R), an oral cancer detection
drug. To date, enrollment to accrue the fewer than 4,000 patients
needed for the multi-center trial is proceeding on schedule. The
trial may be approaching a point where an interim analysis of the
test results could be required. -- In January 2006, the Company
rolled out ViziLite(R) Plus. This product combines its oral
screening technology, ViziLite(R) with TBlue630, a marking system
using Zila Tolonium Chloride (ZTC(R)), the only patented,
pharmaceutical-grade form of toluidine blue. TBlue630 was
FDA-cleared and contains the same active ingredient and formulation
that is used in the Company's OraTest(R) product. -- During fiscal
2006, the Company expanded ViziLite(R) Plus insurance coverage and
added 500 group practices to its customer base, including some of
the largest practices in the country. -- In line with the Company's
strategy to focus on cancer detection and divest non-core assets,
the Company divested IST in July 2006 and closed on the sale of
Zila Nutraceuticals in October 2006. Further, the Company entered
into a non-binding letter of intent to acquire a privately-held
dental products company in order to reach the nation's dentists
through a national sales force. There can be no assurance that this
potential acquisition will be completed. *T "Fiscal 2006 began a
revolutionary transition for Zila as we continued our strategy to
focus our business on high-growth cancer detection technologies. We
succeeded in that mission with growth in ViziLite(R) Plus product
awareness, dental office integration and insurance reimbursement,
while OraTest(R) moved closer to completion of its regulatory
objectives. We were also able to divest our Nutraceuticals business
at a fair valuation in October 2006," said Zila Chairman, President
and CEO, Doug Burkett, Ph.D. Dr. Burkett continued, "As our ongoing
efforts will be focused on growing ViziLite(R) Plus and
subsequently OraTest(R), we sought to acquire a dental company with
a national sales force in order to provide the infrastructure
required to establish our oral cancer detection products as the
standard of care within dental offices nationally. We reviewed over
200 potential dental companies and we have entered into a
non-binding letter of intent to acquire a privately-held dental
products business. We believe this potential acquisition will
enable us to reach the nation's dentists through a highly regarded
and profitable company with a national sales force." The
acquisition, if completed, would provide Zila with a national sales
and marketing organization that has a small suite of proprietary,
high margin dental products that would complement Zila's cancer
screening and detection products. The sales and marketing programs
currently conducted by the target company reflect the focused,
hands-on approach that is required to integrate ViziLite(R) Plus
into dental practices and to establish the test as the standard of
care. The target company generates approximately $35 million in
annual revenue and is profitable. The anticipated acquisition price
is $34 million. There can be no assurance that this potential
acquisition will be completed. -0- *T Fiscal 2006 Fourth Quarter
Results: -- The Company's net revenue for the fourth quarter of
fiscal 2006 was $4.2 million, compared with net revenue of $11.2
million in the fourth quarter of fiscal 2005. -- Zila
Pharmaceuticals' revenue decreased 40% in the fourth quarter to
$1.0 million, compared with $1.7 million during the same quarter of
fiscal 2005. The decline in fourth quarter revenue was primarily
due to lower ViziLite(R) Plus sales as we prepared for a potential
acquisition of a company with a national sales force that would
provide Zila the option to offer ViziLite(R) Plus directly to
dentists. Zila focused its fourth quarter efforts toward the
adoption and integration of ViziLite(R) Plus within dental offices
resulting in continued increases in acceptance, growth and repeat
orders by dental offices as they purchased from dental
distributors. However, deliberate reductions in sales into our
existing distribution channel were made as we optimized our
flexibility to modify and expand our means of distribution. The
upward trend of quarterly ViziLite(R), and subsequently ViziLite(R)
Plus, revenues that were generated during the preceding seven
quarters has been temporarily disrupted to maximize our future
growth options. -- Zila Nutraceuticals' revenue in the fourth
quarter was $3.2 million, compared with $9.5 million during the
prior year's fourth quarter. Zila believes the decrease in sales
was affected by the process of seeking to divest the business unit.
Gross margins for Zila Nutraceuticals were 53% for the three months
ended July 31, 2006 compared with 63% for the three months ended
July 31, 2005. This decrease was caused primarily by discounts
offered to customers to stimulate sales. -- Total operating
expenses for Zila Biotechnology in the fourth quarter was $2.1
million compared with $2.3 million in 2005. This decrease is
primarily due to reduced cost within the Zila Tolonium Chloride
manufacturing facility that was undergoing a recommissioning in the
prior year quarter. *T The Company made progress in the furtherance
of its OraTest(R) regulatory program during the quarter. We believe
that the current study enrollment can be completed in approximately
one year from the beginning of enrollment at most clinical sites in
spring 2006, although no assurances can be given in this regard.
The on-going trial is expected to require fewer than 4,000
patients. Upon completion of the clinical program and assuming that
all clinical requirements are achieved, we estimate that it will
require approximately six months to complete our regulatory
objectives in order to prepare the NDA supplement for submission to
the FDA. Conference Call Zila, Inc. will host a conference call to
discuss these results today at 4:30 p.m. EDT (1:30 p.m. PDT). To
participate in the teleconference, please call toll-free
877-407-8031 (or 201-689-8031 for international callers)
approximately 10 minutes prior to the above start time. You may
also listen to the teleconference live via the internet at
www.zila.com. Investors should visit the website prior to the call
to download any necessary audio software. A telephone playback of
the call will be available for 48 hours, two hours after the
completion of the call, and can be accessed by calling 877-660-6853
(or 201-612-7415 for international callers) and providing passcode
286 and conference ID 215747. The webcast will be archived on the
Company's website for one week. About Zila, Inc. Zila, Inc.,
headquartered in Phoenix, is a leading cancer diagnostic company
initially focused on oral cancer: -- Zila Pharmaceuticals is
dedicated to establishing ViziLite(R)Plus as the new standard of
care within dental offices nationally for the early detection of
oral abnormalities that could lead to cancer. -- Zila Biotechnology
is focused on achieving regulatory approval for the next generation
oral cancer diagnostic, OraTest(R), followed by the development of
additional applications of its cancer detection technologies
including products for the early detection of cervical and
esophageal cancer. For more information about Zila, visit
www.zila.com. This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenue, profitability, cash
flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. The Company makes no
commitment, and disclaims any duty, to update or revise any
forward-looking statements to reflect future events or changes in
expectations. For a more detailed description of these and other
cautionary factors that may affect Zila's future results, please
refer to Zila's Form 10-K for its fiscal year ended July 31, 2006
-0- *T ZILA, INC. AND SUBSIDIARIES Income Statement (Unaudited) (in
thousands, except for per share data) Three Months ended Fiscal
Year ended July 31, July 31, --------------------
-------------------- 2006 2005 2006 2005 ---------- ---------
---------- --------- Net revenues $ 4,207 $ 11,194 $ 28,188 $
43,489 Cost of product sold 2,181 4,021 11,500 14,273 ----------
--------- ---------- --------- Gross profit 2,026 7,173 16,688
29,216 Operating Costs and Expenses: Marketing and selling 2,334
2,128 17,986 15,718 General and administrative 3,890 2,966 13,494
11,040 Research and development 1,565 1,985 7,776 7,181
Depreciation and amortization 742 599 2,727 2,414 ----------
--------- ---------- --------- 8,531 7,678 41,983 36,353 ----------
--------- ---------- --------- Loss from operations (6,505) (505)
(25,295) (7,137) ---------- --------- ---------- --------- Other
income (expense): Interest income 113 59 344 187 Interest expense
(1,255) (52) (2,152) (195) Derivative expense (137) - (137) - Gain
(loss) on sale of assets (1) (2) (27) (6) Other expense (198) (40)
(477) (114) ---------- --------- ---------- --------- (1,478) (35)
(2,449) (128) ---------- --------- ---------- --------- Income
(loss) from continuing operations before tax (7,983) (540) (27,744)
(7,265) Income tax expense - (7) (4) (8) ---------- ---------
---------- --------- Income (loss) from continuing operations
(7,983) (547) (27,748) (7,273) Discontinued operations: Income
(loss) from operations (411) (538) (969) (1,331) Net gain on
disposal of discontinued operations (629) 9,781 (629) 9,781 Income
tax expense - (78) - (78) ---------- --------- ---------- ---------
Income (loss) from discontinued operations (1,040) 9,165 (1,598)
8,372 ---------- --------- ---------- --------- Net income (loss)
(9,023) 8,618 (29,346) 1,099 Preferred stock dividends (10) (10)
(39) (39) ---------- --------- ---------- --------- Net income
(loss) attributable to common shareholders $ (9,033) $ 8,608 $
(29,385) $ 1,060 ========== ========= ========== ========= Basic
and diluted net income (loss) per common share: From continuing
operations$ (0.17) $ (0.01) $ (0.61) $ (0.16) From discontinued
operations (0.02) 0.20 (0.03) 0.18 ---------- --------- ----------
--------- Net income (loss) $ (0.19) $ 0.19 $ (0.64) $ 0.02
Weighted average shares outstanding - basic and diluted 45,749
45,606 45,703 45,565 EBITDA (a) $ (7,061) $ 9,217 $ (24,498) $
3,939 (a) EBITDA is defined as earnings (loss) before net interest,
taxes (income), depreciation and amortization. *T -0- *T EBITDA
Reconciliation (in thousands) Three Months ended Fiscal Year ended
July 31, July 31, --------------------- -------------------- 2006
2005 2006 2005 ----------- --------- --------- ---------- EBITDA $
(7,061) $ 9,217 $(24,498) $ 3,939 Interest income 113 59 344 188
Interest expense (1,256) (52) (2,152) (196) Depreciation and
amortization (819) (599) (3,036) (2,746) Income tax expense - (7)
(4) (86) ----------- --------- --------- ---------- Net Income
(Loss) $ (9,023) $ 8,618 $(29,346) $ 1,099 =========== =========
========= ========== *T -0- *T Net Revenues by Business Unit
Unaudited (in thousands) Three Months ended Fiscal Year ended July
31, July 31, --------------------------- --------------------------
% % 2006 2005 Change 2006 2005 Change --------- -------- -------
--------- -------- ------- Nutraceuticals $ 3,207 $ 9,517 (66) $
21,472 $38,471 (44) Pharmaceuticals 1,001 1,677 (40) 6,716 5,018 34
Total Company 4,208 11,194 (62) 28,188 43,489 (35) *T -0- *T
Balance Sheet Data Unaudited (in thousands) July 31, July 31, 2006
2005 ------------ ----------- Current assets $ 22,970 $ 32,639
Property - net 8,411 9,692 Intangibles - net 22,037 22,614 Other
2,946 473 ------------ ----------- Total assets $ 56,364 $ 65,418
============ =========== Current liabilities $ 29,824 $ 9,815
Long-term liabilities 3,289 3,881 Shareholders equity 23,251 51,722
------------ ----------- Total liabilities and equity $ 56,364 $
65,418 ============ =========== *T
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024